GC Medical Science Corporation

As of March 31, 2026, GC Medical Science Corporation carries a market capitalization of 77.62B, placing it among publicly traded companies globally. Its enterprise value stands at 98.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, GC Medical Science Corporation has 21.74M shares outstanding.

As of March 31, 2026, GC Medical Science Corporation trades at a trailing price-to-earnings ratio of 17.34. The price-to-sales ratio is 0.74, and the price-to-book ratio stands at 1.74.

As of March 31, 2026, GC Medical Science Corporation trades at an EV/EBITDA multiple of 14.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.93 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 36.58 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 98.17B versus a market cap of 77.62B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, GC Medical Science Corporation maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.68, indicating elevated leverage, while an interest coverage ratio of 2.42 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, GC Medical Science Corporation posted a return on equity (ROE) of 10.52, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 4.80, measuring how efficiently the asset base is converted into earnings. The company generates approximately 799.11M in revenue per employee across its workforce of 132.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.00 indicates how many times GC Medical Science Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, GC Medical Science Corporation recorded an income tax benefit of -1.41B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 3.00B, leaving 4.47B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, GC Medical Science Corporation's stock has declined approximately 13.90% over the past 52 weeks. The 50-day moving average sits at 3,242.30, while the 200-day moving average is 3,547.60.

Over the twelve months ended March 31, 2026, GC Medical Science Corporation generated 105.48B in revenue and converted that into 4.47B in net income, yielding earnings per share of 191.96. EBITDA reached 6.65B, while operating income came in at 2.68B.

As of March 31, 2026, GC Medical Science Corporation holds 956.10M in cash and equivalents against 19.42B in total debt, resulting in a net debt position of 11.80B. Total book value stands at 44.52B, with working capital of 5.96B providing operational flexibility.

GC Medical Science Corporation produced 7.02B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -4.02B in capital expenditures, free cash flow totaled 3.00B - equivalent to 137.93 per share.

Over the twelve months ended March 31, 2026, GC Medical Science Corporation posted a gross margin of 13.79, reflecting its pricing power and cost economics. The operating margin of 2.54 and net profit margin of 4.24 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 3.66, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 5.77, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to GC Medical Science Corporation shareholders.

GC Medical Science Corporation's most recent stock split took place on September 30, 2019 with a 37:45 split ratio.

As of March 31, 2026, GC Medical Science Corporation has an Altman Z-Score of 2.69, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.